Kataoka et al., 2024 - Google Patents
Predictors of abemaciclib discontinuation in patients with breast cancer: a multicenter retrospective cohort studyKataoka et al., 2024
View HTML- Document ID
- 10392895634986762764
- Author
- Kataoka N
- Hata T
- Hosomi K
- Hirata A
- Ota R
- Nishihara M
- Kimura K
- Iwamoto M
- Ashida A
- Neo M
- Publication year
- Publication venue
- BMC cancer
External Links
Snippet
Objective This study explored the predictors of abemaciclib discontinuation, a cyclin- dependent kinase 4 and 6 inhibitor, in patients with breast cancer. Material and Methods Between November 2018 and March 2023, 147 patients with breast cancer treated with …
- 229950001573 abemaciclib 0 title abstract description 118
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Andre et al. | Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update | |
Odle | Precision medicine in breast cancer | |
Greenup et al. | Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort | |
Carey et al. | Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | |
Feng et al. | The association of diabetes with risk of prostate cancer defined by clinical and molecular features | |
Bagegni et al. | Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database | |
Collins et al. | A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status | |
Son et al. | Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study | |
Shang et al. | Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients | |
Suzuki et al. | Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: a retrospective study | |
Landgren et al. | Multiple myeloma precursor disease | |
Bruno et al. | Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair–related genes | |
Yoo et al. | Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade | |
Rosenberger et al. | Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis | |
Beebe-Dimmer et al. | Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women’s health initiative | |
Kotsakis et al. | Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study | |
Minucci et al. | BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic | |
Zografos et al. | Germline mutations in a clinic-based series of pregnancy associated breast cancer patients | |
Tada et al. | Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab | |
Kolberg-Liedtke et al. | Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial | |
Lehmann et al. | Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: the TBCRC 043 phase 2 randomized clinical trial | |
Zhao et al. | Identification of hub genes for early detection of bone metastasis in breast cancer | |
Curigliano et al. | Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2–breast cancer | |
Pijnappel et al. | The fear of cancer recurrence and progression in patients with pancreatic cancer | |
Ettl et al. | First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer |